| Bid | 0.7 |
| Market Cap | 444.35M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.13 |
| PE Ratio (ttm) | -5.74 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.72 |
| Volume | 10,354,382 |
| Avg. Volume (20D) | 10,560,444 |
| Open | 0.76 |
| Previous Close | 0.75 |
| Day's Range | 0.71 - 0.80 |
| 52-Week Range | 0.25 - 0.83 |
| Beta | undefined |
About SENS
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a conven...
Analyst Forecast
According to 1 analyst ratings, the average rating for SENS stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 167.95% from the latest price.
Next Earnings Release
Analysts project revenue of $7.79M, reflecting a -2.62% YoY shrinking and earnings per share of -0.03, making a 0.00% YoY.
2 months ago · seekingalpha.com
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call TranscriptSenseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Of...